Contract
Exhibit 10.21
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY “[***].”
SUPPLY AND
PACKAGING SERVICES AGREEMENT
by and between
0000 X. Xxxx Xxxx Xxxx, Xxxxx 000, Xxxxxxx Xxxxx, XX 00000, U.S.
and
Sandoz GmbH
Xxxxxxxxxxxxxxxx 00, 0000 Xxxxx, Xxxxxxx
1.SCOPE AND STRUCTURE OF THIS AGREEMENT3
2.SET-UP ACTIVITIES4
3.PACKAGING AND SUPPLY5
4.CUSTOMER SUPPLIED MATERIALS6
5.FORECASTING, ORDERS AND DELIVERY7
6.PRICES AND PAYMENT TERMS9
7.INTELLECTUAL PROPERTY 10
8.WARRANTIES AND DEFECTIVE PRODUCT11
9.INDEMNIFICATION AND LIABILITIES14
10.QUALITY14
11.PHARMACOVIGILANCE15
12.CONFIDENTIALITY15
13.TERM AND XXXXXXXXXXX00
00.GOVERNING LAW AND JURISDICTION16
15.MISCELLANEOUS17
TABLE OF ANNEXES
Annex 1 – Definitions and Interpretation
Annex 2 – Letter of Intent
Annex 3 – Further Implementation Services
Annex 4 – Bulk Specifications
Annex 5 – Packaging Process
Annex 6 – Prices
Execution Version 2020/12/30Page 2 of 27
This Agreement is made on the date of the last signature of the Parties below (the “Effective Date”)
BETWEEN
(1) |
Sandoz GmbH, a limited liability company organized and existing under the laws of Austria, registered with the commercial register of the district court (Landesgericht) Innsbruck under FN 50587v, with its registered address at Xxxxxxxxxxxxxxxx 00, 0000 Xxxxx, Xxxxxxx (“Supplier”); and |
(2) |
Phathom Pharmaceuticals, Inc, a corporation validly existing under the laws of the State of Delaware, located at 0000 X. Xxxx Xxxx Xxxx, Xxxxx 000, Xxxxxxx Xxxxx, XX 00000, U.S. (“Customer”). |
WHEREAS:
(A) |
Customer is engaged in the marketing and sales of pharmaceutical products. |
(B) |
Supplier is a company engaged inter alia in the manufacturing of pharmaceutical products, including the manufacture of bulk products and provision of packaging services for pharmaceutical products. |
(C) |
Customer desires to entrust Supplier to supply certain bulk products and to perform certain packaging services relating to certain proprietary pharmaceutical products pursuant to the terms and conditions of this Agreement. |
NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein the Parties hereby agree as follows:
1.1 |
Definitions and Interpretation. Unless the context requires otherwise, capitalized terms not defined in the main body of this Agreement shall have the meaning given to such terms in Annex 1 (Definitions and Interpretation) and this Agreement shall be interpreted in accordance with the rules specified therein. |
Vonoprazan 20 mg FCT shall be provided by Customer (the “Customer Provided Bulk Products”), whereas Clarithromycin 500 mg FCTs, Amoxicillin 500 mg HGCs shall be provided by Supplier (the “Supplier Provided Bulk Products”).
Execution Version 2020/12/30Page 3 of 27
that at all times Supplier shall remain the principal obligor for the performance of Supplier’s obligations under this Agreement to the extent not satisfied by an Affiliate of Supplier. This shall include the possibility for Supplier to nominate an Affiliate for order placement and invoicing purposes. Notwithstanding the foregoing, if within [***] following receipt of a notice referred to in the first sentence of this Clause 1.5, Customer notifies Supplier in writing that such proposed Affiliate subcontract by Supplier could impact the Registration for the Final Product, then Supplier agrees not to proceed with such subcontract absent Customer’s prior written consent, which consent shall not be unreasonably delayed, withheld or conditioned, and the Parties will work together in good faith on a plan that would allow Supplier to proceed with such subcontract without impacting the Registration for the Final Product. |
1.7 |
Extension of Scope. The cooperation of the Parties shall in the first instance be limited to Packaging Services, and other services, related to the Final Product to be marketed in the Territory (as defined below). However, Customer intends potentially to launch the Final Product in other regions, and to launch the Additional Product in the Territory and potentially in other regions. In case of such additional launches the scope of this Agreement shall be extended, and the terms modified, solely to the extent necessary to address such expanded scope, e.g., for the Additional Product the Parties would need to agree, among other things, to set up activities, specifications, and pricing, all of which are subject always to mutual agreement of the Parties. |
|
(a) |
Validation of the Packaging Process; and |
|
(b) |
Stability Study for Submission. |
2.4 |
[***] |
Execution Version 2020/12/30Page 4 of 27
3.1 |
Commencement. Upon completion of the Set-up Activities (except for the stability study) and subject to payment of the Implementation Fees, Supplier shall provide the Packaging Services and Deliver Final Products to Customer and its Affiliates throughout the remaining Term. Supplier hereby agrees to supply to Customer and Customer agrees to purchase and accept delivery of the Final Product on the terms and subject to the conditions of this Agreement. |
3.3 |
Packaging Process. The Packaging Process to be followed by Supplier when providing the Packaging Services is defined in Annex 5 (Packaging Process). |
3.4 |
Materials and Equipment. Unless explicitly provided otherwise herein, Supplier shall be responsible for procuring or having available, at its own cost, any and all materials and Equipment necessary for the Packaging Services and the Supplier Bulk Supply, including, for the avoidance of doubt, any Packaging Materials. |
3.5 |
Artwork and Packaging. Customer shall provide or approve, prior to the procurement of applicable components, all artwork and packaging information necessary to Package the Final Product. Customer shall provide artwork for all printed materials (e.g., blister design, cartons, labels and leaflets) at least [***] prior to the placement of the respective Purchase Order. In case of changes in the artworks, text of the package inserts or labeling, Customer shall compensate Supplier [***]. Supplier shall be notified of all changes specific to artworks, package inserts or labeling sufficiently in advance of implementation to allow time for process documentation changes and stock control. Any artwork, advertising and packaging information is and shall remain the exclusive property of Customer, and Customer shall be solely responsible for the content thereof and hold Supplier harmless against any third party claims arising from the use of such artwork etc. in the provision of services hereunder. Such artwork and packaging information or any reproduction thereof may not be used by Supplier following the termination of this Agreement, or during the Term of this Agreement in any manner other than solely for the purpose of performing its obligations hereunder. |
3.6 |
Registration and Regulatory Requirements. Customer and its Affiliates shall be responsible for the Registration of the Final Product with all relevant Regulatory Authorities of all countries of the Territory where they market Final Product. Supplier shall, at Customer’s cost, provide such assistance and information as Customer or its Affiliates may reasonably request in connection therewith, including the grant of a letter of authorization for Supplier’s ANDAs. |
3.8 |
Affiliate Ordering. Supplier agrees that Customer’s Affiliates may order Final Products directly from Supplier in accordance with the terms and conditions of this Agreement, and |
Execution Version 2020/12/30Page 5 of 27
request that Final Products be Delivered directly to such Customer Affiliate together with the appropriate invoices. Any Order placed by a Customer Affiliate and accepted by Supplier shall form a separate and distinct agreement between the parties to such Order. References to either Party in the terms and conditions of this Agreement shall be read as references to the respective Party to any Order for the purpose of said Order. Only the parties to an order shall be bound by such Order. |
4.2 |
Specifications. The Customer Provided Bulk Products and the Supplier Provided Bulk Products shall meet the relevant Bulk Specifications identified in Annex 4. The Customer Provided Bulk Products shall have a bulk holding time of at least [***] from receipt at Supplier’s Facility. |
4.4 |
No Liability of Supplier for Customer Provided Bulk Products. Supplier shall not be liable for any non-compliance with this Agreement to the extent such non-compliance is caused by Customer’s failure to deliver Customer Provided Bulk Products to Supplier on time, in the required quantities or as otherwise agreed between the Parties. |
4.5 |
Handling of Customer Provided Bulk Products. As from their Delivery, Supplier shall: (i) store and handle, at its own cost, Customer Provided Bulk Products in a safe and orderly manner; (ii) identify all such Customer Supplied Materials as goods belonging to Customer; (iii) not mix, alter or analyze Customer Provided Bulk Products except for the purpose of providing the Packaging Services; and (iv) always, except as specifically directed by Customer, use first-expired-first-out (FEFO) methods of usage. |
4.6 |
Yield and Inventory Reconciliation. Once the Process Performance Qualification is completed, the Parties will discuss in good faith and agree on a minimum yield to be achieved by Supplier using the Customer Provided Bulk Product supplied by Customer to Supplier. The Parties presently expect that such minimum yield shall be at least [***]. If the data following completion of the Process Performance Qualification supports a minimum yield that is lower than [***], the Parties agree to work together in good faith to determine the root cause of the problem. Yield is defined as the relation between the Customer Supplied Bulk Product content of the Final Product packaged (actual number of tablets included in Final Product), and the actual quantity of Customer Provided Bulk Product used to manufacture such Final Product. [***]. Supplier will prepare for Customer on an annual basis a written explanation, by lot number, of all variances from the minimum yield. Supplier shall communicate to Customer on a quarterly basis the quantities of Customer Supplied Bulk Products in inventory. |
Execution Version 2020/12/30Page 6 of 27
own costs. Customer shall hold Supplier harmless of any actual, documented losses (including due to production downtime) to the extent directly resulting from such defects or non-conformity, after Supplier has made reasonable good faith efforts to mitigate any such losses (including due to production downtime). |
5.4 |
Changes to Confirmed Orders. Each Party may request changes to a Confirmed Order, including the Confirmed Delivery Dates and/or Confirmed Order Quantities, in which case the Parties shall negotiate in good faith the implementation of such change. |
Execution Version 2020/12/30Page 7 of 27
The Minimum Purchase Quantities for later Launch Years shall be mutually agreed by the Parties at least [***] prior to the end of Launch Year 2. In case the Parties fail to reach an agreement by such date, each Party may terminate this Agreement on [***] prior written notice.
In case Customer fails to order the agreed Minimum Purchase Quantity in a given Launch Year, Customer shall pay to Supplier the difference between the respective aggregated Price (plus VAT) of (i) the quantity of Final Products actually ordered by Customer from Supplier during such Launch Year and (ii) the respective Minimum Purchase Quantity, unless such failure is directly caused by an act or omission solely attributable to Supplier.
5.8 |
Delivery Default. [***] |
5.9 |
No Returns Policy. Supplier will not accept the return of any Final Product sold to Customer except in relation to Defective Final Products and Supplier shall not be liable to Customer in respect of any Final Product purchased by Customer which Customer is subsequently unable to resell. |
Execution Version 2020/12/30Page 8 of 27
Agreement. Except as the Parties may otherwise agree in writing, Supplier and Customer shall share in any cost savings resulting from the implementation thereof based on each Party’s relative contribution (in time and expense) to such implementation, such relative contribution to be mutually agreed upon by the Parties prior to undertaking any such cost saving changes, such agreement not to be unreasonably withheld. Notwithstanding anything to the contrary, each party may withhold its consent to implementation of any cost saving changes in its sole discretion. Promptly following such implementation, the prices for the Final Product payable by Customer as set forth on Annex 6 shall be reduced to reflect Customer’s share of such cost savings. For the avoidance of doubt, an increase in the batch size of the Final Product up to [***] shall not give rise to a price reduction. |
6.4 |
Currency and Payment Terms. All payments pursuant to this Agreement shall be made in Euros and shall be paid within [***] of invoice by bank transfer direct remittance to the bank account designated by Supplier. All invoices sent to Customer shall be sent in .pdf format to [***]. Payments shall be made in full, without deduction of any transfer charges or banking commissions. If any currency conversion will be required in connection with the calculation of any payment hereunder, such conversion will be made by using the exchange rate for purchase of Euros/US Dollars published by the European Central Bank for the respective day the payment was made. |
6.5 |
Taxes and Charges. Customer shall be responsible for the collection, remittance and payment of any or all taxes, charges, levies, assessments and other fees of any kind imposed by any governmental authority or other competent body in respect of the importation, sale, lease or other distribution of the Final Product. |
6.7 |
Unpaid Invoices. Upon expiration or termination of this Agreement all outstanding unpaid invoices shall become payable immediately in place of the payment terms previously agreed by the Parties. |
7.2 |
Customer Intellectual Property. Customer shall in any case retain ownership in or tile to |
|
(a) |
The Packaging Process and the Bulk Specifications relating to the Customer Provided Bulk Products; |
|
(b) |
Any Intellectual Property rights relating to the Final Product and the Customer Provided Bulk Products; |
|
(c) |
The artwork, advertising and packaging information relating to the Final Product; and |
Execution Version 2020/12/30Page 9 of 27
|
(d) |
Any other Intellectual Property solely invented, discovered, generated or derived by Customer or its Affiliates under or in connection with this Agreement and/or the Final Product. |
7.3 |
Supplier Intellectual Property. Moreover, Supplier shall in any case retain ownership in |
|
(a) |
The manufacturing process of Supplier Provided Bulk Products and the Bulk Specifications relating to the Supplier Provided Bulk Products; |
|
(b) |
Any Intellectual Property rights relating to the Supplier Provided Bulk Products; and |
|
(c) |
Any other Intellectual Property solely invented, discovered, generated or derived by Supplier or its Affiliates under or in connection with this Agreement and/or the Supplier Provided Bulk Products. |
7.4 |
Customer's Trademarks. The Final Products shall bear such trademarks, logos and trade names as Customer shall direct. All Intellectual Property rights in such trademarks, logos and trade names shall remain the property of Customer, and Customer shall take all necessary actions and bear all fees to file, register and maintain effective these rights as necessary in the Territory for the Term of this Agreement. |
7.5 |
Supplier Provided Bulk Products License. Supplier hereby grants Customer a non-exclusive, non-transferable, royalty-free license for the Term of this Agreement to use Supplier’s Intellectual Property relating to Supplier Provided Bulk Products solely for the purpose of obtaining and/or maintaining any Marketing Authorizations in the Territory and for marketing, distributing and selling the Final Product in the Territory. Subject to the terms of this Agreement, the license does not grant Customer the right to manufacture or have manufactured by third parties Supplier Provided Bulk Products. For the avoidance of doubt, Supplier shall retain the right to use its Intellectual Property for any purpose inside or outside the Territory, including without limitation (i) the manufacturing, distributing, marketing or sale of the or any finished products containing Supplier Provided Bulk Products on its own, through Affiliates or through third parties inside or outside the Territory; (ii) the licensing of the respective Intellectual Property to other parties inside or outside the Territory who may use such information for similar purposes; or (iii) to sell Supplier Provided Bulk Products in bulk, finished or semi-finished form, or to sell the active pharmaceutical ingredients (API) used for the manufacture of Supplier Provided Bulk Products inside or outside the Territory to any third party or its own Affiliates inside or outside the Territory. |
7.6 |
Packaging Process License. Customer hereby grants Supplier a non-exclusive, non-transferable, royalty-free license or sub-license for the Term of this Agreement to use any Intellectual Property in the Packaging Process and Customer Supplied Materials owned by or licensed to Customer solely for the purpose of performing the Packaging Services. |
8.1 |
Parties’ Warranties. Each Party represents and warrants that |
|
(a) |
it is properly constituted under the laws of the country or state of incorporation and has full power and authority to enter into this Agreement; |
|
(b) |
it has obtained all necessary corporate approvals to enter into this Agreement; |
Execution Version 2020/12/30Page 10 of 27
|
(d) |
it is entitled to grant the rights and licenses to the other Party as set out in this Agreement; |
|
(e) |
it shall obtain and maintain throughout the term of this Agreement all permits, licenses, registration and other forms of government authorization and approval as required by applicable laws in order for each Party to execute and deliver this Agreement and to perform their obligations in accordance with all applicable laws; and |
|
(f) |
it shall comply with all laws, legal and regulatory requirements applicable to performance of its obligations under this Agreement; and |
|
(g) |
in complying with its obligations under this Agreement, neither it, its Affiliates, nor any of its or its Affiliates employees, agents, or permitted Subcontractors, will make payments or provide anything of value to any government official or to any other person knowing that it will be paid or offered to such official or any other person knowing that it will be paid or offered to such official (i) for the purpose of influencing the official to act or make a decision on Customer’s behalf which is in violation of the official’s lawful duty, or (ii) to induce the official to influence any government act or decision in Customer’s favor. |
8.2 |
Supplier Warranties. Supplier represents and warrants that |
|
(a) |
It will perform the Packaging Services in compliance with the Packaging Process and cGMP; |
|
(b) |
Supplier Provided Bulk Products will comply with cGMP, the relevant Bulk Specifications and Supplier ANDAs; and |
|
(c) |
It has full rights and access to the Intellectual Property rights relating to the Supplier Provided Bulk Products, and the supply of the Supplier Provided Bulk Products in line with this Agreement will not infringe any Intellectual Property rights of third parties. |
8.3 |
Customer Warranties. Customer represents and warrants that |
|
(a) |
Customer Provided Bulk Products will comply with the relevant Bulk Specifications; and |
|
(b) |
It has full rights and access to the Intellectual Property rights relating to the Final Products and the Customer Provided Bulk Products, and the provision of the Packaging Services in line with the Packaging Process and the terms of this Agreement – including, for the avoidance of doubt, (i) the import, export, storage and use of Customer Provided Bulk Products in/to the country where the Packaging Services are performed as well as the storage of the Final Products and (ii) the use of the artworks and advertising/packaging provided or approved by Customer for the Packaging Services and Delivery of the Final Product – will not infringe Intellectual Property Rights of third parties. |
8.4 |
No Further Warranties. Except for the express warranties contained in this Agreement, each Party agrees and acknowledges that, except as set forth in this Agreement, neither Party makes any representations or warranties of any kind whatsoever, implied or statutory, and each Party hereby expressly disclaims all representations and warranties, implied or statutory, including any implied warranties of merchantability, fitness for a particular purpose, against non-infringement or the like, or arising from course of performance. |
Execution Version 2020/12/30Page 11 of 27
8.5 |
Notification of Defective Final Products. Customer shall notify Supplier of any claims of Defective Final Product in writing within the following timelines: |
|
(a) |
For Apparent Defects, Customer shall have the right to place a Defective Final Product claim under this Clause 8.5 provided that such claim is made in writing to Supplier within [***] following receipt of the Defective Final Product by Customer at Customer’s warehouse; and |
|
(b) |
For Latent Defects of which it becomes aware during the shelf life of a Final Product, Customer shall have the right to place a Defective Final Product claim under this Clause 8.5 provided that such claim is made in writing to Supplier within [***] following discovery of the Defect. |
In the event that Customer does not notify Supplier of any claims of Defective Final Product in writing within the above timelines, such Final Products shall be deemed free from Defects and accepted by Customer.
|
(a) |
either Party may request in writing for such unresolved dispute to be determined by an independent first-class laboratory; |
|
(b) |
upon receipt of such request, the Parties shall jointly appoint an independent first-class laboratory within [***]. The independent laboratory shall be bound to the Parties by obligations of confidentiality no less exacting than those applying between the Parties pursuant to this Agreement; |
|
(c) |
the independent laboratory shall within [***] following its appointment determine the root cause of the non-conformity or Defect and its findings shall be conclusive and binding upon the Parties; and |
|
(d) |
all fees and expenses of the independent laboratory shall be borne solely by the unsuccessful Party. |
Execution Version 2020/12/30Page 12 of 27
|
(a) |
Any breach by the Indemnifying Party of its representations and warranties given under this Agreement; |
|
(b) |
Negligence, fraud or willful misconduct in performing the Indemnifying Party’s obligations under this Agreement; |
|
(c) |
Any patent infringement or infringement of any other Intellectual Property caused by the Indemnifying Party in performing the Indemnifying Party’s obligations under this Agreement; and/or |
|
(d) |
Any breach of statutory duty or any criminal act by the Indemnifying Party, |
except (in the case of (a) through (d)) to the extent that such losses etc. arise from the breach, negligence or willful misconduct of any Indemnified Party.
10.4 |
Customer Cost. [***]. |
Execution Version 2020/12/30Page 13 of 27
10.5 |
Product Recalls. The rules on recalls of Finished Products are set out in the Quality Agreement. |
11.1 |
General. Customer is responsible for fulfilling its pharmacovigilance obligations arising from its Marketing Authorizations in the Territory. No exchange of pharmacovigilance information applies. |
|
(a) |
is or becomes part of the public domain without a violation of this Agreement; |
|
(b) |
was already in its possession at the time of receipt from the disclosing Party, as shown by documentary evidence; or |
|
(c) |
after the date of this Agreement is received from a third party whose direct or indirect source is not the disclosing Party. |
12.3 |
Survival. The obligations of confidentiality and non-use contained in this Clause 12 shall survive the duration of this Agreement for a period of [***]. |
12.4 |
Return of Confidential Information. Upon termination or expiration of this Agreement for any reason, the receiving Party will promptly return to the disclosing Party all Confidential Information received from the disclosing Party in connection with this Agreement. |
Execution Version 2020/12/30Page 14 of 27
13.2 |
Termination due to Material Breach. Upon failure of any Party to remedy its material breach of any of its obligations under this Agreement (where remediable) on or before [***] after receipt of written notice of said breach from the other Party the Party giving such notice shall have the right but not the obligation to terminate this Agreement immediately (or such longer period of time as such Party shall determine) by written notice. In respect of a material breach which is not capable of remedy, the non-defaulting Party shall have the right, but not the obligation, to terminate this Agreement immediately by written notice on the defaulting Party. |
14.1 |
Governing Law. This Agreement and the legal relations between the Parties in connection herewith shall be governed by, and construed in accordance with, the laws of the England and Wales, excluding the provisions of the United Nations Convention on Contracts for the International Sale of Goods and any conflict of law provisions that would require application of another choice of law. |
15.1 |
Relationship of the Parties. For the purposes of this Agreement, each Party shall be an independent contractor and not an agent or employee of the other Party. Neither Party shall have authority or power to make any statements, representations or commitments of any kind, or to take any action which is binding on the other Party, unless expressly so authorized to do so by an instrument in writing signed by authorized representatives of such other Party. |
Execution Version 2020/12/30Page 15 of 27
such subcontract or supply relationship. If within [***] following receipt of a notice referred to in the second sentence of this Clause 15.2, Customer notifies Supplier in writing that such proposed subcontract by Supplier could impact the Registration for the Final Product, [***]. |
15.3 |
Annexes. All Annexes (and any amendments to such Annexes) and their enclosures form an integral part of this Agreement and are incorporated herein by reference. |
15.4 |
Order of Priority. In the event of any conflict, inconsistency or discrepancy between this Agreement, the Annexes or the terms and conditions referenced or incorporated in this Agreement or the Appendices the following order of priority shall apply: (i) the Quality Agreement (solely in respect of Quality Assurance, quality management and compliance with applicable standards), (ii) this Agreement, (iii) any Annexes, and (iv) individual Orders. |
15.5 |
Standard Terms. Except as expressly otherwise agreed in writing by the Parties, the provisions of this Agreement (including its Annexes) shall apply to any Order for Final Products as well as any activity within the scope of this Agreement. |
15.7 |
Entire Agreement. This Agreement (including the Annexes hereto) constitutes the entire agreement between the Parties related to the subject matter covered by this Agreement, and shall supersede and prevail over any other prior or contemporaneous arrangements regarding this subject matter, whether written or oral, and is binding upon the Parties hereto and their successors. Without prejudice to Clause 15.14, no modification of this Agreement will be binding upon either Party unless made in writing and signed by both Parties. |
15.8 |
Assignment. Unless otherwise provided for herein, this Agreement and the rights and obligations hereunder may not be assigned or transferred by either Party hereto without the prior written consent of the other Party, provided however, that either Party may assign this Agreement (in whole or in part) upon written notice to, but without the prior approval of, the other Party to: (i) an Affiliate; (ii) a third party in connection with the sale or disposal of all or part of the assets of such Party; or (iii) if such Party divests, out-licenses or otherwise disposes of the business or assets relating to the Final Product. |
Execution Version 2020/12/30Page 16 of 27
force and effect and shall be enforceable, and the invalid one shall be replaced by a regulation which meets the original economic intent of the invalid provision as far as legally possible. |
15.10 |
Waiver. No delay or omission on the part of either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any complete or partial waiver on the part of either Party of any right, power or privilege hereunder, nor shall any single or partial exercise or any right, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, power of privilege hereunder. Any provision of this Agreement may be waived if, and only if, such waiver is in writing and signed by the Party against whom the waiver is to be effective. |
15.11 |
Survivorship. Any of the provisions of this Agreement, including the Annexes, that are expressed or implied to survive the expiration or termination of this Agreement, shall remain in full force and effect. |
15.12 |
Publicity. Neither Party will make any press release or other public disclosure regarding this Agreement or the transactions contemplated hereby without the other Party’s express prior written consent, except as required under applicable laws, by any governmental agency or by the rules of any stock exchange on which the securities of the disclosing Party are listed, in which case the Party required to make the press release or public disclosure shall provide the other Party with a draft of such form, nature and extent of the press release or public disclosure prior to issuing the press release or making the public disclosure, and shall consider in good faith any comments provided by the non-disclosing Party. |
15.13 |
Execution. This Agreement may be executed in two or more counterparts, each of which, when executed, shall be an original, but all counterparts shall together constitute one and the same instrument. |
[SIGNATURE PAGE FOLLOWS]
Execution Version 2020/12/30Page 17 of 27
IN WITNESS WHEREOF, the Parties have signed this Agreement on the dates set out below:
For and on behalf of Sandoz GmbH
|
For and on behalf of Phathom Pharmaceuticals, Inc |
Signature: /s/ Xxxxxxx
|
Signature: /s/ Xxxxxx Xxxxxx |
Name: Xxxxxxx Xxxxxx
|
Name: Xxxxxx Xxxxxx
|
Title: President, Global B2B |
Title: Chief Executive Officer |
Date: December 30, 2020 |
Date: December 30, 2020 |
For and on behalf of Sandoz GmbH
|
For and on behalf of Phathom Pharmaceuticals, Inc |
Signature: /s/ Xxxx Xxxxxxxxxx
|
Signature: /s/ Xxxx Xxxxxxx
|
Name: Xxxx Xxxxxxxxxx
|
Name: Xxxx Xxxxxxx
|
Title: Director Business Partnering Global B2B |
Title: Chief Operating Officer |
Date: December 30, 2020 |
Date: December 30, 2020 |
Execution Version 2020/12/30Page 18 of 27
Annex 1
DEFINITIONS AND INTERPRETATION
1. |
Defined Terms |
The following terms shall, unless the context otherwise requires, have the respective meanings set out below and grammatical variations of such terms shall have corresponding meanings:
“Additional Product” means a pharmaceutical product in final packaged form (including with package leaflet and instructions for use) containing [***].
“Affiliate” means any corporation or other business entity which, directly or indirectly, is controlled by, controls, or is under common control with Customer or Supplier as the case may be. For such purposes, “Control” shall mean the direct or indirect ownership of at least fifty percent (50%) of the voting interest in such corporation or other entity or the power in fact to control the management directions of such entity.
“Agreement” means this Supply and Packaging Services Agreement.
“Annex” means an annex to this Agreement.
“Apparent Defect” means any Defect which is visible or easily detectible through routine incoming quality control measures.
“Background Intellectual Property” has the meaning in Clause 7.1.
“Batch” means a defined quantity of Final Products, Bulk Products, Customer Supplied Materials or any other materials used for the Packaging Services, processed in one process or series of processes, so that it could be expected to be homogeneous.
“Bulk Products” has the meaning in Clause 1.3.
“cGMP” means current Good Manufacturing Practices promulgated by the Regulatory Authorities in the jurisdictions included in Applicable Laws. In the United States, this includes 21 C.F.R. Parts 210 and 211, as amended; and in Europe, this includes 2003/94/EEC Directive (as supplemented by Volume 4 of EudraLex published by the European Commission), as amended, if and as implemented in the relevant constituent country.
“Claims” has the meaning in Clause 9.1.
“Clause” means a clause of this Agreement.
“Confidential Information” has the meaning in Clause 12.1.
“Confirmed Delivery Date” has the meaning in Clause 5.3.
“Confirmed Order” has the meaning in Clause 5.3.
“Confirmed Order Quantities” has the meaning in Clause 5.3.
“Customer” has the meaning attributed to it in the preamble of this Agreement.
“Customer Provided Bulk Products” has the meaning in Clause 1.3.
“Defective Final Product” refers to Final Products that do not conform to the Packaging Process and/or that contains Supplier Provided Bulk Product that does not conform to the Supplier Bulk Specifications. “Defect” shall be interpreted accordingly.
“Deliver” or “Delivery” means the delivery of the Final Product by Supplier pursuant to Clause 5.10.
“Effective Date” has the meaning attributed to it in the preamble of this Agreement.
Execution Version 2020/12/30Page 19 of 27
“Equipment” means any equipment and machinery required in the provision of the Packaging Services hereunder.
“Exclusive Purchase Period” has the meaning in Clause 3.7.
“Extended Term” has the meaning in Clause 13.1.
“Facility” means Supplier’s manufacturing facility located at [***] and as may be amended from time to time.
“FDA” means the U.S. Food and Drug Administration.
“Final Product” means the following pharmaceutical products in final packaged form (including with package leaflet and instructions for use) which is the end product of the Packaging Services as defined in Annex 3, and includes the Additional Product, if any.
“Force Majeure” has the meaning in Clause 15.6.
“Forecast” has the meaning in Clause 5.1.
[***]
“Further Implementation Services” has the meaning in Clause 2.3.
“Indemnified Party” has the meaning in Clause 9.1.
“Indemnifying Party” has the meaning in Clause 9.1.
“Initial Term” has the meaning in Clause 13.1.
“Intellectual Property” means patents (whether patentable or not), trade secrets, know-how, confidential or proprietary information, technical data, trademarks, service marks, design rights, copyright or any other intellectual property right which may subsist anywhere in the world, whether capable of grant, registration or not.
“Latent Defect” means any Defect other than Apparent Defects.
“Launch” means the first commercial sale of the Final Product in the Territory to a third party.
“Launch Year” means each twelve (12) month period commencing upon Launch of the Final Product. The first 12-month period following Launch shall be referred to as “Launch Year 1”, the second 12-month period following Launch shall be referred to as “Launch Year 2”, etc.
“LoI” means the letter of intent entered into between the Parties on letter of intent on August 27. 2020, a copy of which is attached hereto as Annex 2.
“Manufacturing Phase” has the meaning in Clause 1.6.
“Marketing Authorization” means, in respect of a Final Product, such marketing authorization, approval, license, registration or other authorizations issued by a Regulatory Authority in connection with the placing of that Final Product on the market in the Territory.
“Minimum Capacity” has the meaning in Clause 5.5.
“Minimum Order Quantities” has the meaning in Clause 5.6.
“Minimum Purchase Quantities” has the meaning in Clause 5.7.
“Order” has the meaning in Clause 5.2.
“Order Lead Time” has the meaning in Clause 5.2.
“Package” or “Packaging” means (as applicable) any and all activities relating to the Packaging Services, including the packaging, preparation, testing, handling, storage and supply of Final Products in accordance with the terms of this Agreement.
Execution Version 2020/12/30Page 20 of 27
“Packaging Material(s)” means, collectively, any primary and/or secondary packaging materials (including any leaflets and instructions for use) as well as any other components necessary to provide the Packaging Services according to the terms of this Agreement.
“Packaging Process” means the process to be followed when providing the Packaging Services, as described in detail in Annex 3 (Packaging Process).
“Packaging Services” means any and all services in relation to the Packaging of the Bulk Products to be carried out by or on behalf of Supplier in line with the Packaging Process, including without limitation the receipt of materials, primary and/or secondary packaging (as the case may be), processing, testing, quality control, releasing, storing, sample retention, serialization and packaging for shipment.
“Parties” means the Supplier together with Customer, each individually may be referred to as a “Party”.
“Quality Agreement” means the quality agreement to be entered into by the Parties (or their Affiliates) in line with Clause 10.1.
“Quality Assurance” or “QA” means the sum total of the quality assurance arrangements made with the purpose of ensuring that the Final Product meets the Specifications and is of the quality required for its intended use and shall specifically include all terms and activities as set forth in the applicable version of the Quality Agreement.
“Registration” means any and all governmental or Regulatory Authority approvals necessary or required for the processing, Packaging, importation, marketing, distribution and sale of the Final Product as labeled, packaged and presented for sale to the pharmaceutical trade, and the term “Registration” shall also apply to any renewals of such approvals and to any other steps required to maintain such approvals.
“Regulatory Authority” means any international, national or other governmental, regulatory or administrative authority or other body competent to grant, maintain and extend approvals (including pricing), registrations or other consents for the processing, Packaging, importation, marketing, distribution or sale of pharmaceutical products, including without limitation the Final Products.
“Representatives” has the meaning in Clause 12.1.
“Requested Delivery Date” has the meaning in Clause 5.2.
“Requested Order Quantities” has the meaning in Clause 5.2.
“Set-up Phase” has the meaning in Clause 1.6.
“Set-up Activities” has the meaning in Clause 2.1.
“Subcontractor” has the meaning in Clause 15.2.
“Supplier” has the meaning attributed to it in the preamble of this Agreement.
“Supplier ANDAs” means [***], certain abbreviated new drug applications filed by Supplier with the FDA for certain finished products containing the Supplier Provided Bulk Products.
“Supplier Bulk Specifications has the meaning in Clause 3.2.
“Supplier Bulk Supply” has the meaning in Clause 1.2.
“Supplier Provided Bulk Products” means Supplier’s proprietary pharmaceutical products specified Clause1.3 to be manufactured by Supplier or its Affiliates and to be provided by Supplier in addition to the Packaging Services and to be included in the Final Products.
“Term” has the meaning in Clause 13.1.
Execution Version 2020/12/30Page 21 of 27
“Territory” means the United States of America.
“VAT” means within the European Union such taxation as may be levied in accordance with (but subject to derogation from) Council Directive 2006/112/EC and outside the European Union any taxation levied by reference to added value or sales.
2. |
Interpretation. |
In this Agreement unless otherwise specified:
|
(a) |
the division of this Agreement into Clauses, sub-clauses and Annexes and the insertion of headings are for convenience of reference only and shall not affect the interpretation of this Agreement; |
|
(b) |
the terms “this Agreement”, “hereof”, “herein”, “hereunder” and similar expressions refer to this Agreement; |
|
(c) |
a statute or statutory instrument or any of their provisions is to be construed as a reference to that statute or statutory instrument or such provision as the same may have been or may from time to time hereafter be amended or re-enacted; |
|
(d) |
all references to the singular shall include the plural and vice versa; |
|
(e) |
the term “including” shall mean “including without limitation”; and |
|
(f) |
any reference in this Agreement to a “day” or “week” shall be references to a calendar day or week. Where express reference is made to “business day(s)” any such reference shall mean a day (with the exception of Saturday and Sunday) on which banks are open in Austria and New York, New York. |
Execution Version 2020/12/30Page 22 of 27
LETTER OF INTENT
[***]
Execution Version 2020/12/30Page 23 of 27
FURTHER IMPLEMENTATION SERVICES
[***]
Execution Version 2020/12/30Page 24 of 27
BULK SPECIFICATIONS
[***]
Execution Version 2020/12/30Page 25 of 27
Annex 5
Packaging Process
Finished Products - Specifications:
[***]
Process Flow Chart:
[***]
Execution Version 2020/12/30Page 26 of 27
PRICES
Product Price and MOQ
[***]
Execution Version 2020/12/30Page 27 of 27